Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease with Basiliximab and Etanercept in Early Period
Y. Tan,Y. Luo,J. Shi,J. He,Y. Zhao,X. Lai,W. Zheng,J. Sun,Y. Zheng,Z. Cai,M. Lin,H. Huang
DOI: https://doi.org/10.1016/j.bbmt.2010.12.550
2011-01-01
Biology of Blood and Marrow Transplantation
Abstract:Severe acute graft-versus-host disease (aGVHD) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Steroid-resistant aGVHD(SR-aGVHD) is especially associated with a high incidence of mortality. We performed a prospective study in treatment of grades III-IV SR-aGVHD in early period with a combination of anti-cytokine therapy composed of IL-2 receptor antibody (basiliximab) and TNF-receptor fusion protein (etanercept) from June 2009 to Agust 2010. Seven patients experienced grade IV SR-aGVHD (skin involved in seven patients, gastro-intestinal involved in six patients, liver involved in four patients). The median age was 23 years (range 11-48). Donor types were HLA-matched related (n = 1), HLA-matched unrelated (n = 2), and haploidentical related (n = 4). Anti-cytokine therapy consisted of intravenous basiliximab 20mg on days 1, 4, 8, 15, and etanercept 25 mg subcutaneous twice a week for 4 weeks, followed by once weekly for 4 more weeks. All patients (100%) achieved complete remission. Five of 7 (71.4%) patients are currently alive with a median follow-up of 163 (80–348) days after transplantation, and a median follow-up of 121 (48–321) days after Anti-cytokine therapy. Only two patients died of pulmonary infection and cardiac arrest. In our retrospectivly studied in twenty-three patients with SR-aGVHD who reveiving allo-HSCT from HLA-matched related donor (n = 1), HLA-mismatched related donor (n = 1),HLA-matched unrelated donor (n = 6), HLA-misatched unrelated donor (n = 15), the treatment of SR-aGVHD included high dose methylprednisolone, anti-thymocyte globulin, basiliximab or etanercept, respectively. Only five(21.7%) patients achieved CR and two(8.69%) achieved partial remission. Only five of 23 (21.7%) patients are currently alive with a median follow-up of 52 (32–3697) days after transplantation.The incidence of treatment-related mortality (TRM) was 78.3%. The cause were infectious complications and organ failure. Inflammatory cytokines, IL-2 and TNF-a, play critical roles in the pathological of GVHD, and may be effective targets for therapy. Our data suggested that the combination of basiliximab and etanercept is well tolerated and can induce a high response rate, high survival rate with low incidence of TRM in patients with severe SR-aGVHD in early period, particularly in sever GrmonaryI aGVHD.